1. Market Research
  2. > Pharmaceutical Market Trends
  3. > China Pharmaceutical Excipients Industry Report, 2014-2017

China Pharmaceutical Excipients Industry Report, 2014-2017

  • November 2014
  • -
  • Research In China
  • -
  • 101 pages

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are also contained in pharmaceutical preparations after reasonable safety assessment.

China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-propylene glycol, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, hydroxypropyl cellulose (HPC) and lactose rank as the top 10 pharmaceutical excipients in China.

Among them, the traditional pharmaceutical excipients --gelatin capsules are involved with adequate supply and large export volume. In H1 2014, China’s gelatin capsule export volume amounted to 1,427.5 tons and the export value hit USD32.408 million. However, China still relies on the import of film-coated powder, polyvinylpyrrolidone (PVP) and other new-type high-end pharmaceutical excipients.

Currently, pharmaceutical excipients account for about 2%-3% of China's total output value of pharmaceutical preparations. Chinese pharmaceutical excipient market size reached about RMB26.35 billion in 2013 and is expected to be RMB54.83 billion in 2017.

There are about 400 pharmaceutical excipient manufacturers in China, of which over 90 ones or 23% specialize in the production of pharmaceutical excipients, while most of the remaining ones focus on chemical or food processing.

Currently, foreign leading pharmaceutical excipient companies, such as Colorcon (the USA), Degussa (Germany), Meggle (Germany) and Roquette (France), have set up joint ventures, wholly-owned companies or offices in China. Colorcon mainly provides film-coated products; Meggle pharmaceutical lactose, and Roquette pharmaceutical starch and polyols.

Chinese pharmaceutical excipient giants include Er-Kang Pharmaceutical, Sunhere Pharmaceutical Excipients, Dongbao Bio-Tech, Qinghai Gelatin, Shandong Liaocheng A Hua Pharmaceutical, Zhanwang Pharmaceutical and Qufu Tianli, but their market concentration rate is rather low. As a tycoon, Er-Kang Pharmaceutical only seized about 2.7% market share in 2013.

Ranking among the largest Chinese pharmaceutical excipient producers with the most complete types, Er-Kang Pharmaceutical holds 116 types of pharmaceutical excipients and the capacity of 45,000 tons or more. Over the past two years, the company has continued to enforce epitaxial expansion strategy and accelerate market layout. In March 2014, the company acquired 100% stake in Changsha Zhengyang Pharmaceutical Capsule and 51% stake in Hunan Dongting Citric Acid Chemicals. In addition, the company’s 180,000 tons/a medicinal cassava starch production project went into operation on March 31, 2014; the first phase of "South China Pharmaceutical Excipient Base Construction Project" has been completed and will realize production goal at the end of 2014.

Sunhere Pharmaceutical Excipients is a Chinese member of International Pharmaceutical Excipient Confederation (IPEC), mainly producing microcrystalline cellulose, hydroxypropyl cellulose, hypromellose and other 18 types of new-type pharmaceutical excipients with the capacity of 10,000 tons. On April 24, 2014, Sunhere Pharmaceutical Excipients planned to go public so as to raise funds for 7,100 tons/a new-type pharmaceutical excipient production line expansion project.

Zhanwang Pharmaceutical produces 28 types of pharmaceutical excipient products including carboxymethyl starch sodium, pre-gelatinized starch, hypromellose, microcrystalline cellulose, etc., with the capacity of over 10,000 tons. Some production bases of the company have passed the certification of the US FDA and the European COS. Now, export has contributed 25% to the company’s revenue.

The report includes the following aspects:
Operating environment (including economy, policies, barriers to entry, upstream and downstream environment) of China pharmaceutical excipient industry;
Status quo, competition pattern, import & export and development trend of China pharmaceutical excipient industry;
Operation, pharmaceutical excipient business and prospects of 10 major Chinese pharmaceutical excipient companies;
Development forecast and operation comparison between major enterprises in China pharmaceutical excipient industry.

Table Of Contents

China Pharmaceutical Excipients Industry Report, 2014-2017
1 Overview of Pharmaceutical Excipients
1.1 Overview
1.2 Classification

2 Operating Environment of China Pharmaceutical Excipient Industry
2.1 Economy
2.2 Policies
2.3 Entry Barriers
2.3.1 Qualification
2.3.2 R and D and Technology
2.3.3 Marketing Channels and Brands
2.3.4 Funds
2.4 Upstream and Downstream Environment
2.4.1 Upstream
2.4.2 Downstream

3 Development of China Pharmaceutical Excipient Industry
3.1 International Market
3.2 Status Quo
3.3 Competition Pattern
3.4 Import and Export
3.4.1 Import
3.4.2 Export
3.5 Breakdown Products
3.5.1 Pharmaceutical Gelatin
3.5.2 Hydroxypropyl Methyl Cellulose (HPMC)
3.5.3 Pharmaceutical Starch
3.5.4 Pharmaceutical Sucrose
3.5.5 Propanediol
3.6 Development Trend
3.6.1 Marketing Channels and Brand Building Are Strengthened
3.6.2 The Industry Heads toward Production Specialization and Standardization
3.6.3 The Varieties of Pharmaceutical Excipients Increase
3.6.4 Downstream Pharmaceutical Preparation Industry Boosts Pharmaceutical Excipient Industry
3.6.5 Industrial Concentration Rate Will Ascend Gradually
3.6.6 Technological Development Turns the Focus to Security, Functionality, Adaptability, Efficiency, etc.
3.6.7 Composite Excipients Will Be One Development Direction of Pharmaceutical Excipients

4 Major Companies
4.1 Er-Kang Pharmaceutical
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R and D and Investment
4.1.6 Pharmaceutical Excipient Business
4.1.7 Forecast and Outlook
4.2 Sunhere Pharmaceutical Excipients
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R and D and Investment
4.2.6 Output and Sales Volume
4.2.7 Supply
4.2.8 Forecast and Outlook
4.3 Dongbao Bio-Tech
4.3.1 Profile
4.3.2 Revenue
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R and D and Investment
4.3.6 Pharmaceutical Excipient Business
4.3.7 Forecast and Outlook
4.4 Qinghai Gelatin
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Pharmaceutical Excipient Business
4.4.6 Forecast and Outlook
4.5 Shandong Head
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R and D and Investment
4.5.6 Pharmaceutical Excipient Business
4.5.7 Output and Sales Volume
4.5.8 Supply
4.5.9 Forecast and Outlook
4.6 Shandong Liaocheng A Hua Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Pharmaceutical Excipient Business
4.7 Zhanwang Pharmaceutical
4.7.1 Profile
4.7.2 Operation
4.7.3 Pharmaceutical Excipient Business
4.8 Qufu Tianli
4.8.1 Profile
4.8.2 Pharmaceutical Excipient Business
4.9 North China Pharmaceutical
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Pharmaceutical Excipient Business
4.10 Joinway Pharmaceutical
4.10.1 Profile
4.10.2 Pharmaceutical Excipient Business

5 Forecast and Outlook
5.1 Industrial Development Forecast
5.2 Operation Comparison between Major Enterprises
5.2.1 Revenue
5.2.2 Net Profit
5.2.3 Net Profit Margin
5.2.4 Gross Margin
5.2.5 Pharmaceutical Excipient Business

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.